Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
Journal: Journal for immunotherapy of cancer
Published: August 04, 2021
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Journal: Cancer medicine
Published: March 20, 2019
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
Journal: Investigational new drugs
Published: November 25, 2018
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 25, 2017
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 22, 2016
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 18, 2014
Showing 1-6 of 6
Last Updated: 09/26/2026